Imdevimab

imdevimab · Regeneron Pharmaceuticals

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Imdevimab, covering 2023-03-06 to 2025-10-14. Get the full timeline:

Most recent: Clinical Trial Update: COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers [Phase 1]

See pricing